Literature DB >> 15193395

Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).

Jeff Alexander1, Marie-France del Guercio, Barbara Frame, Ajesh Maewal, Alessandro Sette, Moon H Nahm, Mark J Newman.   

Abstract

Experimental carbohydrate-conjugate vaccines composed of the 13 amino acid universal Pan HLA-DR Epitope (PADRE) and Streptococcus pneumoniae capsular polysaccharides from serotypes 14, 6B and 9V were produced. Simple carbodiimide-mediated condensation chemistry was used to conjugate the PADRE synthetic peptide to the three chemically different capsular polysaccharides in a 1:1 molar ratio. The immunogenicity of the PADRE peptide component of the conjugate vaccines was confirmed by the induction of PADRE-specific CD4+ helper T cell (HTL) responses following immunization of C57BL/6 mice. High titer antibody responses specific for polysaccharides of S. pneumoniae serotypes 14, 6B and 9V were induced using Complete Freund's Adjuvant (CFA) and alhydrogel Al(OH)3 formulations. The HTL, or carrier, effect of the PADRE synthetic peptide was only evident using the PADRE-polysaccharide conjugates; simple mixtures of the PADRE peptide and polysaccharides were essentially nonimmunogenic. The functional or potential protective value of the polysaccharide-specific antibodies was measured as a function of opsonophagocytic activity for the 6B serotype. High titers of opsonophagocytic activity were measured in sera from mice immunized with formulations containing both adjuvants. These data demonstrate that the PADRE synthetic peptide can induce the HTL responses needed to support the development of antibodies specific for bacterial carbohydrates used in conjugate vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193395     DOI: 10.1016/j.vaccine.2003.11.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen.

Authors:  E Paulovicová; E Machová; A Hostacká; S Bystrický
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

3.  Synthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicity.

Authors:  Joan G Schellinger; Lieza M Danan-Leon; Jessica A Hoch; Aemro Kassa; Indresh Srivastava; David Davis; Jacquelyn Gervay-Hague
Journal:  J Am Chem Soc       Date:  2011-02-22       Impact factor: 15.419

4.  The capsular polysaccharide biosynthesis of Streptococcus pneumoniae serotype 8: functional identification of the glycosyltransferase WciS (Cap8H).

Authors:  Nehmé Saksouk; Ludovic Pelosi; Pierre Colin-Morel; Manel Boumedienne; Patricia L Abdian; Roberto A Geremia
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

5.  Properties of antibodies to a synthetic peptide representing an epitope shared by receptors of the type I cytokine family.

Authors:  Carlos G Belloc; Marisol Aguirre; Clara Peña; José L Aparicio; Maite Duhalde Vega; Sarah Dormois; Lilia A Retegui
Journal:  Clin Exp Med       Date:  2013-02       Impact factor: 3.984

6.  The wciN gene encodes an α-1,3-galactosyltransferase involved in the biosynthesis of the capsule repeating unit of Streptococcus pneumoniae serotype 6B.

Authors:  Weiqing Han; Li Cai; Baolin Wu; Lei Li; Zhongying Xiao; Jiansong Cheng; Peng G Wang
Journal:  Biochemistry       Date:  2012-07-13       Impact factor: 3.162

7.  Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand.

Authors:  Renato B Baleeiro; Karl-Heinz Wiesmüller; Lars Dähne; Jürgen Lademann; José A Barbuto; Peter Walden
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

8.  Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation.

Authors:  Chao-Yi Wu; Archana Monie; Xiaowu Pang; Chien-Fu Hung; T-C Wu
Journal:  J Biomed Sci       Date:  2010-11-22       Impact factor: 8.410

9.  Design, Construction and Cloning of Truncated ORF2 and tPAsp-PADRE-Truncated ORF2 Gene Cassette From Hepatitis E Virus in the pVAX1 Expression Vector.

Authors:  Fatemeh Farshadpour; Manoochehr Makvandi; Reza Taherkhani
Journal:  Jundishapur J Microbiol       Date:  2015-12-13       Impact factor: 0.747

10.  Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.

Authors:  Haniyeh Ghaffari-Nazari; Jalil Tavakkol-Afshari; Mahmoud Reza Jaafari; Sahar Tahaghoghi-Hajghorbani; Elham Masoumi; Seyed Amir Jalali
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.